OncoVee™-mini-patient-derived xenograft guided adjuvant chemotherapy treatment for resectable gastric cancer

Table 3 Univariate and multivariate Cox proportional hazards regression analysis of recurrence-free survival

Characteristics	Mean recurrence-free survival months	P value	Multivariate adjusted hazard ratio (95% confidence interval)1	P value
Treatment		0.025	0.266 (0.087-0.816)	0.021
MiniPDX group, n = 16	48.2 (37.9-58.5)
Experimental treatment group, n = 20	32.7 (23.7-41.7)
Age group		0.286	NA	NA
≤ 60, n = 24	42.0 (32.6-51.4)
> 60, n = 12	32.3 (22.8-41.7)
Sex		0.336	NA	NA
Male, n = 22	42.7 (33.6-51.7)
Female, n = 14	32.3 (21.9-42.7)
T-stage of primary tumor1		0.100	NA	NA
pT1, n = 10	46.0 (33.6-58.3)
pT2, n = 8	49.1 (35.4-62.8)
pT3, n = 15	32.8 (22.5-43.0)
pT4, n = 3	15.7 (3.5-27.9)
N-stage of primary tumor1		0.027	NA	NA
N0, n = 19	42.6 (32.5-52.8)
N1, n = 6	54.3 (40.6-68.1)
N2, n = 2	31.5 (0.0-67.8)
N3, n = 9	25.7 (13.3-38.1)
Stage of AJCC1		0.018	NA	NA
Stage 1, n = 16	46.0 (35.8-56.2)		0.536 (0.330-0.869)2	0.011
Stage 2, n = 9	45.8 (30.8-60.8)		0.542 (0.349-0.840)3	0.06
Stage 3, n = 11	26.8 (15.6-38.0)		1.6884	0.194

¹Tumor stage was defined according to the American Joint Committee on Cancer tumor-node-metastasis staging system (8^th edition).

²Multivariate Cox analysis results for American Joint Committee on Cancer stage 1 vs stages 2 + 3 in subjects (stage 1, n = 16; stage 2 + 3, n = 20).

³Multivariate Cox analysis results for American Joint Committee on Cancer stage 1 + 2 vs stages 3 in subjects (stage 1 + 2, n = 25; stage 3, n = 11).

⁴Multivariate Cox analysis results for American Joint Committee on Cancer stage 2 vs stages 3 in subjects (stage 2, n = 9; stage 3, n = 11).

MiniPDX: Mini patient-derived xenograft; AJCC: American Joint Committee on Cancer; NA: Not available.